Chargement en cours...
Immunotherapies and Future Combination Strategies for Head and Neck Squamous Cell Carcinoma
Head and neck squamous cell carcinoma (HNSCC) is often diagnosed at an advanced stage and has a dismal prognosis. Nearly 10 years after the approval of cetuximab, anti-PD1/PD-L1 checkpoint inhibitors are the first drugs that have shown any survival benefit for the treatment on platinum-refractory re...
Enregistré dans:
| Publié dans: | Int J Mol Sci |
|---|---|
| Auteurs principaux: | , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
MDPI
2019
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6862353/ https://ncbi.nlm.nih.gov/pubmed/31671550 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms20215399 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|